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Pravin Manga, MBBCH, PHDT he global burden of human immunodeﬁ-ciency virus (HIV) has largely been borne byAfrica, particularly sub-Saharan Africa (1). In
the sub-Saharan region, South Africa has the largest
population of HIV-infected individuals, with an esti-
mated 6 million living with HIV (1). HIV is no longer
a fatal illness, which is largely the result of treatment
with highly active antiretroviral treatment (HAART).
As a result, the life expectancy of HIV-infected indi-
viduals has increased substantially compared with
the pre-HAART era.
On the African subcontinent, the major subtype
of HIV is the HIV-1, group M (major) subtype C,
which accounts for 55% to 60% of all HIV-1 in-
fections worldwide (2). To date, the majority of re-
search on cardiovascular disease in HIV-infected
patients has been performed in Caucasian patients
infected with HIV-1 subtype B, which differs as
much as 30% in its genome from HIV-1 subtype C
(2,3). However, in sub-Saharan Africa, there are
scant data on the risk of cardiovascular disease in
HIV-positive populations, and thus, the risk of car-
diovascular disease in HIV-infected African patients
is largely unknown. Also of importance is that some
countries, particularly South Africa, have managed
to introduce an active HAART program for a sig-
niﬁcant number of individuals with HIV. However,
many other developing nations in Africa, due to
limited resources, have far fewer individuals being
treated with antiretroviral therapy. Thus, there
are 2 groups of HIV patients living in Africa, those
not on HAART and those on HAART, leading to
different challenges for managing cardiovascular
disease in Africa.ardiology, Department of Internal Medicine,
es, University of Witwatersrand, Johannesburg,HIV AND PERICARDIAL DISEASE
Pericardial disease poses a signiﬁcant health care
problem in sub-Saharan Africa. Small pericardial ef-
fusions are common and largely asymptomatic in
HIV-infected individuals, but they do presage a worse
outcome compared with those without pericardial
effusion (4). Because tuberculosis is endemic, the
suspicion of infection with mycobacterium tubercu-
losis is very high with larger effusions, and it has been
found to be the cause of pericardial disease in the vast
majority (86% to 100%) of these individuals (5).
Mortality from tuberculous pericarditis and HIV in
sub-Saharan Africa, in spite of therapy, ranges be-
tween 17% and 40% and is twice as high compared
with those without HIV (6). Some early studies sug-
gested a beneﬁt of adjunctive steroid therapy in pa-
tients with HIV and tuberculous pericarditis with
regard to improved mortality and decreased inci-
dence of constrictive pericarditis (7). To clarify this
important clinical issue, a large randomized study of
prednisolone and immunotherapy in constrictive
pericarditis was performed in a number of clinical
sites all over Africa (8). The recently published results
of that study demonstrated that, in HIV patients with
tuberculous pericardial effusion, not only did the
addition of steroid therapy fail to reduce the primary
endpoint of mortality, but importantly, the addition
of steroids was associated with a signiﬁcantly higher
risk of cancer in these patients (8).
HIV AND CORONARY ARTERY DISEASE
Studies in developed countries report a 1.5- to 2-fold
increase in cardiovascular events related to coronary
artery disease in HIV-infected patients (the majority
of whom are on HAART) compared with control
populations (9). The underlying mechanism of early
atherosclerosis in HIV disease is not well under-
stood, and suggested mechanisms include vascular
J A C C V O L . 6 6 , N O . 5 , 2 0 1 5 Manga
A U G U S T 4 , 2 0 1 5 : 5 8 6 – 8 Guest Editor’s Page
587inﬂammation leading to endothelial dysfunction and
possibly the effect of antiretroviral treatment (10,11).
Because of the huge burden of HIV in sub-Saharan
Africa, it was expected that there would be a signiﬁ-
cant increase in the prevalence of coronary artery
disease. However, this has not materialized. The
Heart of Soweto Study found that, in the cohort of
cardiac patients admitted to the hospital and who
were diagnosed with HIV—one-half of whom were on
HAART—the overall prevalence of coronary artery
disease was only 2.4% (12). The low prevalence may
be related to a much younger population in this re-
gion and low use of protease inhibitors.
The common ﬁndings in cohorts from both devel-
oped and developing countries is that the mean age at
diagnosis of acute coronary syndrome is a decade
younger and subjects are more likely to be male, be
current smokers, have lower high-density lipoprotein
levels, and have single-vessel disease on coronary
angiography (12–14). Additionally, the South African
cohort of HIV patients with acute coronary syn-
dromes had less atherosclerotic burden angiograph-
ically but a signiﬁcantly higher degree of thrombus
burden in the infarct-related artery (14). The throm-
botic burden in these patients is thought to be related
to a prothrombotic state with lower protein C and
higher factor VIII levels (15).
HIV AND CARDIOMYOPATHY
HIV-related cardiomyopathy is a signiﬁcant contrib-
utor to morbidity and mortality in sub-Saharan Africa,
with prevalence ranging from 9% to 57% and in-
hospital mortality of up to 15% (16). The pathogen-
esis of the cardiomyopathy in these HIV-infected
patients is unknown. Many hypotheses have been
proposed, including direct invasion of the myocar-
dium by the HIV virus, autoimmunity and immune
dysregulation, endothelial dysfunction, and beta-
adrenergic dysregulation (17). Initiation of antiretro-
viral therapy is important to decrease this burden as
the introduction of HAART has been associated withalmost a 50% reduction in prevalence of HIV-
associated cardiomyopathy (18).
EFFECT OF HIV ON HEALTH CARE AND
RESEARCH IN AFRICA
The HIV epidemic infection has had a devastating
effect on health care provision, resources, and life
expectancy in Africa. The introduction of HAART,
albeit in limited capacity in many parts of Africa, has
dramatically improved life expectancy of many of
these patients. However, many countries in sub-
Saharan Africa are a long way from providing a
comprehensive prevention program, as well as
effective antiretroviral therapy for all infected with
HIV. As antiretroviral therapy is associated with a
signiﬁcant reduction in HIV-related cardiovascular
diseases, the strategies for prevention and treatment
of HIV-related heart disease in developing countries
has been to support the active campaigns to get uni-
versal access to HAART in the ﬁrst place. Conse-
quently, the major research focus in sub-Saharan
Africa has largely been directed to prevention and
treatment strategies of HIV infection itself. Very little
research emphasis has been placed on speciﬁc targets
such as the inﬂuence of HIV on heart disease. How-
ever, the expected improved survival related to pro-
gressively more patients being treated with HAART
will be an ideal platform for researchers in Africa to
study the various aspects of cardiovascular disease in
HIV patients, both in those who are HAART naïve and
in those receiving HAART. Of note, the National
Institutes of Health recently identiﬁed various re-
search “gaps” in our knowledge of HIV and heart
disease and has encouraged investigation in these
areas (19).
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